{
    "nct_id": "NCT03778957",
    "official_title": "A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)",
    "inclusion_criteria": "* No evidence of extrahepatic disease\n* Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE\n* Child-Pugh score class A to B7 and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment\n* Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria\n* Adequate organ and marrow function\n\nKey Exclusion Criteria\n\n* Any history of nephrotic or nephritic syndrome\n* Clinically significant cardiovascular disease or history of arterioembolic event including a stroke or myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within 6 months prior to randomization\n* Any prior or current evidence of coagulopathy or bleeding diathesis or patients who had any kind of surgery in the past 28 days (biopsies are exempt from this exclusion)\n* History of abdominal fistula or GI perforation, non healed gastric ulcer that is refractory to treatment, or active GI bleeding within 6 months prior to enrollment\n* Patients with Vp3 and Vp4 portal vein thrombosis on baseline imaging are excluded\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 110 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": "Key"
}